

151 Tetanus

REFERENCES

1. Thwaites CL, Farrar JJ: Preventing and treating tetanus. *BMJ* 326: 117, 2003.
2. Roper MH, Vandelaer JH, Gasse FL: Maternal and neonatal tetanus. *Lancet* 370: 1947, 2007.
3. Pascual FB, McGinley EL, Zanardi LR, et al: Tetanus Surveillance—United States, 1998–2000. *MMWR Surveill Sum* 52: 1, 2003.
4. McQuillan GM, Kruszon-Moran D, Deforest A, et al: Serologic immunity to diphtheria and tetanus in the United States. *Ann Intern Med* 136: 660, 2002.
5. Hopkins RS, Jajosky RA, Hall PA: Summary of notifiable disease—United States, 2003. *MMWR Morb Mortal Wkly Rep* 52: 1, 2005.
6. Centers for Disease Control and Prevention. Epidemiology and Prevention of Vaccine-Preventable Diseases, 10th ed. Atkinson W, Hamborsky J, McIntyre L, Wolfe S (eds). Washington, DC, Public Health Foundation, 2008.
7. Cook TM, Protheroe RT, Handel JM: Tetanus: a review of the literature. *B J Anaesth* 87: 477, 2001.
8. Pinder M: Controversies in the management of severe tetanus. *Intensive Care Med* 14: 129, 1997.
9. Rethy L, Rethy LA: Human lethal dose of tetanus toxin. *Lancet* 350: 1518, 1997.
10. Mellanby J, Green J: How does tetanus toxin act? *Neuroscience* 6: 281, 1981.
11. Thwaites CL, Yen LM, Loan HT, et al: Magnesium sulphate for treatment of severe tetanus: a randomized controlled trial. *Lancet* 368: 1436, 2006.
12. Thwaites CL, Yen ML, Cordon SM: Effect of magnesium sulphate on urinary catecholamine excretion in severe tetanus. *Anaesthesia* 63: 719, 2008.
13. Abrahamian FM, Pollack CV, LoVecchio F, et al: Fatal tetanus in a drug abuser with “protective” antitetanus antibodies. *J Emerg Med* 18: 189, 2000.
14. Blake PA, Feldman TM, Buchanan TM, et al: Serologic therapy of tetanus in the United States, 1965–1971. *JAMA* 235: 42, 1976.
15. Ahmadsyah I, Salim A: Treatment of tetanus: an open study to compare the efficacy of procaine penicillin and metronidazole. *Br Med J* 291: 648, 1985.
16. Powles AB, Ganta R: Use of vecuronium in the management of tetanus. *Anaesthesia* 40: 879, 1985.
17. Borgeat A, Popovic V, Schwander D: Efficiency of a continuous infusion of propofol in a patient with tetanus. *Crit Care Med* 19: 295, 1991.
18. James MF, Manson ED: The use of magnesium sulfate infusions in the management of very severe tetanus. *Intensive Care Med* 11: 5, 1985.
19. Buchanan N, Smit L, Cane RD, De Andrade M: Sympathetic overactivity in tetanus: Fatality associated with propranolol. *Br Med J* 2: 254, 1978.
20. King WW, Cave DR: Use of esmolol to control autonomic instability of tetanus. *Am J Med* 91: 425, 1991.
21. Kretsinger K, Broder KR, Cortese MM, et al: Preventing tetanus, diphtheria and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine. *MMWR Recomm Rep* 55: 1, 2006.

USEFUL WEB RESOURCES

World Health Organization Information—<http://www.who.int/topics/tetanus/en>
Centers for Disease Control and Prevention: Tetanus—<http://www.cdc.gov/vaccines/vpd-vac/tetanus/default.htm>